

Announcement no. 12/2007

To OMX the Nordic Exchange

Copenhagen, June 1, 2007

Total share capital and total number of votes in Curalogic A/S

Under section 17(2) of Executive Order no. 226 of 15 March 2007 on the disclosure requirements of issuers, we hereby announce that, as of today, Curalogic A/S' share capital totals DKK 18,214,408 divided into 36,428,816 shares of DKK 0.50 corresponding to 36,428,816 voting rights.

Yours sincerely,

Curalogic A/S

For additional information, please contact:

Peter Moldt, President and CEO, Phone +45 33 11 41 01, mobile +45 26 25 04 22
Helle Busck Fensvig, EVP and CFO, Phone +45 33 11 41 01, mobile +45 20 70 55 37

About Curalogic

Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the treatment of allergy. By combining the best of two worlds - the efficacy of immunotherapy combined with the safety and patient convenience of symptomatic treatments – Curalogic aims to develop a novel and user-friendly form of allergy treatment, and make it the preferred type of allergy treatment among patients. Curalogic has a broad and mature pipeline with a product for treatment of ragweed allergy in Phase III, a product for treatment of grass allergy ready for Phase III, a product for treatment of cat allergy in Phase II and a product for treatment of house dust mite allergy preparing for clinical trials.

This announcement contains forward-looking statements regarding the company's future financial development and performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of the company's knowledge, are reasonable at this time, but may prove to be erroneous in the future.